PropThink: BioCryst and Presidio’s Priorities May Shift with FDA Concerns

[ACN Newswire] – By Jake KingChalk another nuc up to the FDA’s growing list of safety-related development interruptions. On Tuesday, BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that it has withdrawn an … more

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard